Physician profile
Avi B Markowitz
NPI 1336155662
$12,854.98
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $1,798 · 2021: $234 · 2022: $271 · 2023: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $287.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $7,066.34 | 2019 | |
| Pfizer INC. | $1,972.67 | 2020-2023 | |
| Seagen INC. | $1,887.38 | 2019 | |
| Athenex Pharmaceutical Division, LLC | $521.72 | 2019 | |
| Genentech USA, INC. | $376.24 | 2019-2021 | |
| Celgene Corporation | $267.04 | 2019-2023 | Reblozyl |
| Rigel Pharmaceuticals, INC. | $258.73 | 2019-2020 | |
| Genmab U.S., INC. | $124.99 | 2023 | Epkinly |
| Foundation Medicine, INC. | $91.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $71.37 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $37.04 | 2019 | |
| Lilly USA, LLC | $23.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.82 | 2019 | |
| Emd Serono, INC. | $19.66 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.56 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avi Markowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.